RxDoctor Payments Data

Frank Cao, MD

Glaucoma Specialist · Stockton, CANPI 1366703969

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 27.7% of the total. Reporting peaked in 2022 at $397 and has fallen 63.7% since, to $144 in 2025. That places this record below the midpoint for glaucoma specialist clinicians in CA, where the typical reported total is $4,143.

$1,843in general payments, 2019–2025

Across 55 payments — averaging $33.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$511
  • Alcon$321
  • Aerie Pharmaceuticals, Inc.$157
  • Ivantis, Inc$149
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$135
  • Ocular Therapeutix, Inc.$125
  • plus $445 from 9 others

What the payments were for

  • Food & beverage$1,82599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,843 in reported general payments places this provider in the 35th percentile of 64 glaucoma specialist providers in California.

See all glaucoma specialist providers in California

Medicare billing

Part B allowed, 2024
$89,895
Medicare patients
392
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost39$24,939
Prednisolone Acetate283$16,637
CequaCyclosporine16$16,086
RestasisCyclosporine15$12,946
Cyclosporine25$10,397
VyzultaLatanoprostene Bunod20$8,862
RocklatanNetarsudil Mesylat/Latanoprost20$8,300
Latanoprost386$8,076
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat223$5,695
Brinzolamide17$4,262
Fml ForteFluorometholone16$3,760
Timolol Maleate178$3,488
Acetazolamide ErAcetazolamide29$2,562
Travoprost17$2,538
TafluprostTafluprost/Pf12$2,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$79$37,88654 claims
Sun Pharmaceutical Industries Inc.Cequa$511$16,08616 claims
Bausch & Lomb Americas Inc.Vyzulta$32$8,86220 claims
Aerie Pharmaceuticals, Inc.Rocklatan$157$8,30020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 64 glaucoma specialist providers in California.

Other glaucoma specialist in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →